Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

  • Technology appraisal guidance
  • TA1023
  • Published: 

Information for the public

Elranatamab (Elrexfio) is available during the managed access period. It is a possible treatment for multiple myeloma in adults that has come back (relapsed) or stopped responding to treatment (refractory). It can only be used:

  • after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome inhibitor and an anti‑CD38 antibody), and
  • when the multiple myeloma has got worse on the last treatment.

Lines of treatment are a sequence of treatments, starting with the best option and moving to alternatives if the first does not work or the condition gets worse. Each line can be a single drug or a combination of drugs.

More evidence on elranatamab is being collected. After this, NICE will decide whether to recommend elranatamab for use on the NHS and update the guidance. It will be available with managed access until then.

If you are not eligible for elranatamab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on making decisions about your care.

Questions to think about

  • How well does it work compared with other treatments?
  • What are the risks or side effects? How likely are they?
  • How will the treatment affect my day-to-day life?
  • What happens if the treatment does not work?
  • What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The NHS webpage on multiple myeloma may be a good place to find out more.

These organisations can give you advice and support:

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6662-2

This page was last updated: